FOR IMMEDIATE RELEASE

BioStratum Announces JBC Publication on the Anti-Angiogenic Activity of Type IV Collagen Non-Collagenous Domains - Angiocol™
-- Integrin Binding Activity Shown as Part of a Multi-Functional Anti-Angiogenesis Mechanism of Action--

Research Triangle Park, N.C., -- March 21, 2000-- BioStratum Incorporated, the world leader in basal
lamina research, announced today the publication of a paper in the March 17th issue of the Journal of Biological Chemistry (volume 275, pages 8051-8061) reporting on the
anti-angiogenic activity of the non-collagenous domains of type IV collagen.

In this paper, the non-collagenous domains of three of the six chains of type IV collagen are shown to possess potent anti-angiogenic activity, i.e. they inhibit new blood vessel growth. Administration of these non-collagenous domains, referred to as Angiocol™, is shown to dramatically inhibit capillary development and tumor growth in the well established CAM animal model system. Similar results have been seen in a mouse/human chimera animal model, which uses grafted human skin with implanted human tumors (unpublished results). BioStratum is currently scaling up the production of these potent anti-angiogenesis agents and will soon initiate their clinical evaluation.

Previously, BioStratum announced the issuance of US Patent #5,856,184 to the University of Kansas Medical Center on the anti-angiogenic and anti-tumor activities of the non-collagenous domain of type IV collagen, which
is exclusively licensed to BioStratum. In addition, the Company has exclusive rights to US Patent #5,973,120, #5,731,192, and #5,114,840, which cover the sequences
of these anti-angiogenic non-collagenous domains.

The initial discovery of this unique anti-angiogenic activity was made by Drs. Billy Hudson and Michael Sarras at the University of Kansas Medical Center, in collaboration with BioStratum Incorporated. Dr. Hudson has been studying the structure and function of type IV collagen for over 25 years, and is an internationally renowned expert in type IV collagen. He also discovered two of the six chains of type IV collagen.

"In studying the assembly and organization of type IV collagen into a biologically active basal lamina, we discovered that the addition of the non-collagenous domain of type IV collagen disrupted the process," said Dr.Hudson. "Realizing the requirement for a functional basal lamina
in the development of new blood vessels, we examined
the anti-angiogenic activity of these domain structures in
Mike Sarras's laboratory and found them to be potent inhibitors of capillary growth. Our collaborative work
with Dr. Peter Brooks, as presented in this JBC paper, demonstrates that the observed anti- angiogenic activity
of these domains is also mediated through interactions
with integrin receptors that have been shown to be key to the angiogenesis process."

"These domains are some of the most potent
anti-angiogenesis agents we have studied in our laboratory," said Dr. Peter Brooks of the Department
of Biochemistry and Molecular Biology at the University
of Southern California, and the senior author of the published work. "Their binding to integrin receptors,
which are known to be important in the angiogenesis process, in conjunction with their key role in the assembly of type IV collagen, probably accounts for their potent
anti-angiogenic effect."

"We are particularly excited about Angiocol™, because
of its demonstrated high potency and multi-functional mechanism of action," said Dr. Claus Kuhl, president
and CEO of BioStratum Incorporated. "Since many factors stimulate angiogenesis, targeting only one site may not lead to an efficacious treatment. We believe the best approach to effectively inhibit angiogenesis is to interrupt the formation of a functional basal lamina, as it is involved in numerous molecular interactions that direct the growth and development of new capillaries."

Plans for Angiocol™ clinical trials include its use as an adjunctive therapy in metastatic cancers for which few effective therapies are available, including malignant melanoma and colorectal cancer. It is anticipated that Angiocol™ will be administered in association with chemotherapy and/or radiotherapy. The product will
most likely be administered once or twice a week over
the course of a patient's treatment period, which is estimated to be six to twelve months.

BioStratum Incorporated, based in Research Triangle Park, N.C., is a privately held biotechnology company developing proprietary therapeutics based on scientific advances in type IV collagen, basal lamina, and related technologies. The company's drug candidates are directed against novel basal lamina extracellular targets involved in degenerative and invasive disease processes fundamental to kidney disease, diabetes and cancer. The company has also developed methods for the production of recombinant basal lamina proteins for use in wound repair and advanced tissue regeneration protocols.

###